Eflornithine in Treating Patients With Bladder Cancer

Completed · Phase 3

Conditions studied: Bladder Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if eflornithine is more effective than no further therapy in treating bladder cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of eflornithine in treating patients who have newly diagnosed or recurrent bladder cancer.

Key facts

Study ID
NCT00003814
Run by
National Cancer Institute (NCI)
People needed
450
Starts
1999-02-01
Expected to finish
2007-05-01
Last updated by the study team
2013-12-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.